GlaxoSmithKline to Acquire Tesaro for $4.16 Billion -- Update
03 Dezembro 2018 - 2:55PM
Dow Jones News
By Kimberly Chin
GlaxoSmithKline PLC on Monday said it would buy cancer-focused
drug company Tesaro Inc. for about $4.16 billion, positioning the
health-care giant in a promising, but fiercely competitive, area of
medicine.
Britain's Glaxo has agreed to pay $75 a share in cash for the
Waltham, Mass.-based company, a premium of 61% on its closing price
Friday. Including debt, the deal is valuated at $5.1 billion.
The acquisition hands Glaxo Tesaro's ovarian cancer drug Zejula,
which went on sale in the U.S. and Europe last year. Zejula is one
of a new class of drugs known as PARP inhibitors, which have
increased survival rates for women with recurrent ovarian cancer.
PARP inhibitors are also showing promise in other forms of cancer,
such as lung, breast and prostate.
But in buying Zejula, Glaxo is entering a competitive arena.
AstraZeneca PLC's Lynparza is the market leader and a third PARP
inhibitor from Boulder, Colo.-based biotech company Clovis Oncology
is also jostling for market share. All three are also racing to
test their PARP inhibitors in other cancer types.
Zejula's sales have lagged rivals, with doctors and industry
officials saying the treatment's side-effect profile is worse than
the other drugs.
These concerns have given would-be buyers of Tesaro pause in the
past. The company unsuccessfully explored the possibility of a sale
more than a year ago. Since then, before Monday's announcement, its
share price has fallen.
Glaxo investors appeared cool on the deal Monday, with its
shares falling almost 8%. Analysts expressed surprise at the deal,
pointing to the apparent lack of overlap with Glaxo's existing
cancer pipeline and Zejula's less favorable side-effect profile.
Tesaro's stock soared nearly 59%.
Glaxo's Chief Scientific Officer Hal Barron said a clinical
study that is due to publish results in the first half of next year
could expand Zejula's use to women at an earlier stage of ovarian
cancer, boosting sales.
Dr. Barron also pointed to a growing body of research suggesting
that PARP inhibitors combined with other cancer drugs could prove
powerful in treating a range of cancers that exhibit a particular
genetic defect.
"This is just the tip of the iceberg," he said. "We'll start
learning about cancers with these defects and how to treat them."
He said Glaxo would test out Zejula in combination with drugs in
its own cancer-drug pipeline as well as those under development at
Tesaro.
Glaxo is doubling down on its prescription-pharmaceutical
business under new Chief Executive Emma Walmsley, who has been
trimming the company's research and development activities to focus
on drugs that either work on the immune system or target diseases
where a genetic driver can be identified.
Glaxo's focus was also apparent Monday with a separate deal to
sell its nutrition business in India, including the Horlicks brand,
to Unilever PLC.
The deal marks a return to selling cancer drugs for Glaxo, which
unloaded its oncology portfolio to Novartis AG in 2014 as part of a
$20 billion three-part transaction, while retaining its pipeline of
early-stage oncology medicines. Dr. Barron said drugs such as
Zejula fit with Glaxo's new strategy because they are based on a
gene-level understanding of the disease.
Glaxo said that it doesn't expect the acquisition to add to
earnings until 2022. That is in part because it will invest heavily
in further research on Zejula, on its own and in combination with
other drugs, and on selling the drug. The U.K.-based company
reaffirmed its guidance for the fiscal year 2018, expecting
adjusted per-share earnings growth to be between 8% and 10%.
The transaction is expected to be completed in the first quarter
of 2019.
--Jonathan Rockoff contributed to this article.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
December 03, 2018 11:40 ET (16:40 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Tesaro, Inc. (NASDAQ:TSRO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Tesaro, Inc. (NASDAQ:TSRO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024